Evidence-based · Educational only•
36+ Peptides indexed•
Free research library•
Free newsletter — subscribe below•
★ = FDA-approved medical indication•
Not medical advice — always consult a clinician•
Evidence-based · Educational only•
36+ Peptides indexed•
Free research library•
Free newsletter — subscribe below•
★ = FDA-approved medical indication•
Not medical advice — always consult a clinician•
Peptide Knowledge Center
All peptides

Exenatide

Also known as: Byetta / Bydureon
FDA-Approved

Exenatide is a GLP-1 mimetic derived from exendin-4, available in twice-daily and once-weekly formulations.

Buy Exenatide on American Peptides

Affiliate link — we may earn a commission at no extra cost to you.

Overview

Exenatide is a GLP-1 mimetic derived from exendin-4, available in twice-daily and once-weekly formulations.

FDA Approval Status

Approved by the FDA for at least one medical indication (see approved uses below).

Mechanism of Action

GLP-1 receptor agonism.

Current Research

Long clinical history in T2D management.
Research strength: Strong

Potential Medical Uses

  • Type 2 diabetes

Potential Benefits

  • Glycemic control
  • Modest weight reduction

Known Side Effects

  • Nausea
  • Injection-site nodules (weekly form)

Contraindications

  • Severe renal impairment (twice-daily form)
  • MTC/MEN 2

Drug Interactions

  • Warfarin (monitor INR)

Administration Methods

  • Subcutaneous injection

Half-life

~2.4 hours (Byetta); extended (Bydureon)

Reconstitution

Prefilled or single-dose kits per label.

Storage & Handling

Refrigerate.

References & Sources

Frequently Asked Questions

Information on this page is educational and general in nature. It is not medical advice. Consult a qualified healthcare professional before making any medical decisions.